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102 Poster Session-IIrate, the proportion of these units meeting storage criteria is low.
Of the 448 units collected in this study, only 19.2% met banking
guidelines as compared to 22.0% for Caucasians, 26.7% for
Asians, and 20.0% for Hispanics. African American units not
meeting storage criteria were deferred primarily for low volume
(54.7%) and total nucleated cell count (25.2%). Acknowledging
that biologic factors negatively impact the recovery of nucleated
cells from cord blood collected from this population, the SLCBB
is currently designing a Phase II study to assess alternative
methods to increase collection volumes and cellular yield for
African American donors.279
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Monitoring of T-cell chimerism after nonmyeloablative(NMA)
regimens has been used to identify patients at risk for graft rejection,
relapse and acute and chronic graft-versus host disease and to deter-
mine use and timing of donor lymphocyte infusions. Followingmye-
loablative (MA) transplantation chimerism studies are not considered
useful because T-cell engraftment is thought to occur rapidly . We
analyzed T-cell engraftment following NMA (fludarabine/TBI)
and after MA transplantation generally busulfan-based. T-cell chi-
merism was studied in 116 patients following MA (busulfan-based
in 72) and 99 patients following NMA transplantation between 5/
2000 and 11/2007, using STR of CD31 cells at 30, 60 and 90 days.
The estimated median interval to T-cells $ 50% donor was 29
days after MA and 27 days after NMA and to T-cells$90% donor
was 42 and 44 days respectively. Comparing only the 72 patients
receiving busulfan based MA preparation to the NMA patients,
T-cell chimerism$10% (p\0.001) and$50% (p5 0.029) occurred
more quickly after NMA transplantation. There was no difference
(p 5 0.68) in the interval to$90% donor T-cells. T-cell
chimerism.50% was associated with more acute GVHD (p 5
0.02), less graft rejection (p\0.001) and less relapse (p5 0.05) follow-
ing NMA regimens, while T-cell chimerism.90% was associated
with more chronic GVHD (p 5 0.002). In MA transplants,
chimerism.50% and .90% were associated with more acute
GVHD (p 5 0.04, p 5 0.009), and chimerism.90% was associated
withmore chronicGVHD (p5 0.07). InNMA,multivariate analysis
found that patients with AML (p5 0.02) and more prior chemother-
apy(p50.04)weremore likely to reach chimerism.50%,while those
with a diagnosis of AML (p5 0.04), MDS (p5 0.002) or CLL (p5
0.05) were more likely to reach chimerism.90%. In MA, multivari-
ate analysis found that patients with more prior chemotherapy (p 5
0.05) and peripheral stem cells (p5 0.008) were more likely to reach
chimerism.90%. These data demonstrated that T-cell engraftment
occurred more quickly in NMA thanMA transplants using busulfan.
Factors predictive of T-cell engraftment kinetics were similar in
NMA and MA transplantation. The preparative regimen is only
one of many factors determining the kinetics of T-cell engraftment.
Designation of a regimen as myeloablative does not correlate with
more rapid or complete T-cell engraftment.
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PRE-EMPTIVE TREATMENTWITH CIDOFOVIR FOR SYMPTOMATIC BK VI-
RUS POSITIVE PATIENTS WHO UNDERWENT ALLOGENEIC STEM CELL
TRANSPLANT REDUCES THE RISK OF PROGRESSION TO HEMORRHAGIC
CYSTITIS
Bilodeau, A., Phillips, J., Mapara, M., Raptis, A., Hou, J.-Z., Agha, M.
Univ. of Pittsburgh Medical Center, Pittsburgh, PA
We have previously demonstrated that Polyomavirus BK asso-
ciated hemorrhagic cystitis is becoming an increasingly recog-
nized complication of HSCT. Our previously published
retrospective analysis demonstrated that BKV was observed in
48% of patients undergoing an allogeneic stem cell transplant
and 16% of them developed hemorrhagic cystitis. Based on therecent findings, we designed a prospective protocol for pre-emp-
tive treatment with Cidofovir for symptomatic BK Viruria. 39
patients underwent an allogeneic stem cell transplant from either
an HLA-matched sibling or unrelated donor during fiscal year
2008. Patients who manifested urological symptoms received Ci-
dofovir 375mg IV QOW until all symptoms resolved. Out of 39
of these patients, 59% (23/39) developed BK virus infection
determined using quantitative real-time PCR assay. Out of these
23 patients, 61% (14/23) received a myeloablative conditioning
regimen (Bu/Cy, TBI/Cy) and 39% (9/23) a non myeloablative
(Flu/TBI, Flu/Cy/Rituxan, Cy/ATG/TBI, TBIx1, Flu/Mel/
Campath, Flu/Cy/TBI). 30% (7/23) became symptomatic and
subsequently received Cidofovir 375mg IV QOW which was
continued until all symptoms resolved and 71% (5/7) also re-
ceived Ciprofloxacin. 57% (4/7) had Graft Versus Host Disease
and 86% (6/7) were concurrently receiving high dose steroid
therapy. 71% (5/7) developed mild hematuria and 29% (2/7) de-
veloped small thrombus in the urine. The mean of total Cidofo-
vir doses received was three and the two patients who developed
mild hematuria with thrombus received 5 and 6 doses respec-
tively. Bone marrow suppression was noted in three patients
who received Cidofovir which was consequently either held or
completely discontinued. All 7 patients had complete resolution
of symptoms, and none developed any clinical manifestations of
hemorrhagic cystitis defined as gross hematuria or the need of
continuous bladder irrigation. There was no correlation with
symptoms and BK virus PCR titers. In conclusion, pre-emptive
treatment of symptomatic BK Viruria with Cidofovir in the allo-
geneic stem cell transplant setting is safe and effective and poten-
tially prevents the progression to BK virus induced hemorrhagic
cystitis.281
GERIATRIC ASSESSMENT (GA) MAY IDENTIFY VULNERABLE OLDER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) RECIPI-
ENTS
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Comorbidity indices and performance status (PS) have been the
primary tools used to predict HCT tolerance; however, these tools
suffer from poor discriminative capacity. Geriatric Assessment
(GA) has found widespread application to assess reduced physio-
logic reserve (i.e. vulnerability) among elderly adults. We hypoth-
esized that a modified GA would identify vulnerable HCT
recipients 50 years and older. We supplemented the standard
pre-HCT evaluation (e.g. history, laboratory, PFT’s) with a pro-
spective GA integrating multiple geriatric domains. Among 94 pa-
tients (pts) 50 years and older, 91 consented to the GA. The
median age was 58 (range 50 – 72). Conditioning regimens were
primarily fludarabine/melphalan, fludarabine/busulfan, and clo-
farabine/melphalan with alemtuzumab and tacrolimus for immu-
nosuppression. The comorbidity domain was scored using four
tools: Charlson Comorbidity Index (CCI), Kaplan Feinstein Scale
(KF), Hematopoietic Cell Transplantation-Comorbidity Index
(HCT-CI) and the Cumulative Illness Rating Scale-Geriatric
(CIRS-G). Functional domains were estimated by PS, frailty index
(FI), and the physical health portion of the short form 36 (SF36-
PH) whereas the mental health portion of the SF36 (SF36-MH)
measured mental health. Activities of daily living (ADL) and in-
strumental ADL (IADL) assessed disability. Table 1 describes
the results and variation detected by each tool within each geriat-
ric domain. For comorbidity, the CIRS-G was the most sensitive
tool as every pt showed comorbidity. Among functional measures,
PS was normal (i.e. PS 5 0) in most pts (64%). Only 4% had a PS
of 2. In contrast, the FI and SF36-PH demonstrated functional
limitations in the majority of pts. Specifically, 52% were
‘‘pre-frail’’ (FI of 1 – 2) and 29% were frail (FI of 3–5). Disability
by ADL or IADL was rare. A modified GA in older HCT recipi-
ents is feasible and may reveal abnormalities in multiple geriatric
domains suggesting vulnerability not recognized by a standard
evaluation. Ongoing studies will determine the predictive validity
of specific domains within the GA.
